TMCnet - World's Largest Communications and Technology Community


TMCNET eNEWSLETTER SIGNUP "Stocks that Standout" picks for today are: ACOR, ERII, GENZ, PGOG, PGYC, SCII
[March 31, 2009] "Stocks that Standout" picks for today are: ACOR, ERII, GENZ, PGOG, PGYC, SCII

(M2 PressWIRE Via Acquire Media NewsEdge) RDATE:31032009 "Stocks that Standout" picks for today are: Acorda Therapeutics, Inc. (NASDAQ: ACOR), Energy Recovery, Inc. (NASDAQ: ERII), Genzyme Corporation (NASDAQ: GENZ), Perf Go Green Holdings, Inc.

(OTCBB: PGOG), Patriot Energy Corporation (PINKSHEETS: PGYC), Stem Cell Therapy International, Inc. (OTCBB: SCII)...and Proudly Introducing Proprietary Push Technology (PPT).

The Newest and Revolutionary Technology for Increasing Investor Visability.

REAL Awareness for REAL Companies.

Click below for a full demonstration. Sign-up for our FREE Stock Alerts AND AWARD WINNING NEWSLETTER at Mar 31, 2009 -- Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced today that the Company received a refuse to file letter from the U.S.

Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for Fampridine-SR, a novel therapy being developed to improve walking ability in people with multiple sclerosis (MS).

The FDA has raised what it termed "format issues" regarding the eCTD (electronic) submission, requesting that some of the data in the NDA be reformatted, as well as requesting that some additional supporting information be included in the filing. The FDA has not requested or recommended additional clinical or other studies.

"We are surprised by this development," stated Ron Cohen, M.D., President and CEO of Acorda Therapeutics, "We plan to address the issues raised in this letter with FDA expeditiously as we believe Fampridine-SR is potentially an important, first in class treatment option for people suffering with MS." The Company plans to request a meeting with FDA as soon as possible to discuss its comments on the NDA filing.

Conference Call and Audiocast corda will host a conference call Tuesday, March 31, 2009 at 8:30 a.m.

Eastern Time. To participate, please dial 866-783-2143 (domestic) or 857-350-1602 (international) and reference the access code 85118409. To access the audio webcast, please go to the Investor Relations "Calendar of Events" section of the Acorda website, or you may use the link: ventID=2150210.

A replay of the call will be available from 11:30 a.m. Eastern Time on March 31, 2009 until April 30, 2009. To access the replay, please dial 888-286-8010 (domestic) or 617-801-6888 (international) and reference the access code 59152215. The archived teleconference will be available for 30 days in the Investor Relations section of the Acorda website at

About Acorda Therapeutics Acorda Therapeutics is a biotechnology company developing therapies for spinal cord injury, multiple sclerosis and related nervous system disorders. The Company's marketed products include Zanaflex Capsules(R) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. The Company's pipeline includes a number of products in development for the treatment, regeneration and repair of the spinal cord and brain.

Mar 31, 2009 -- Energy Recovery, Inc. ("ERI") (NASDAQ: ERII), a global leader of ultra-high-efficiency energy recovery products and technology for desalination, was awarded the 75,000 m(3)/day (20 million US Gallons (MGD)) energy recovery technology contract from Acciona Agua for the Paraguana seawater reverse osmosis (SWRO) desalination plant in Venezuela. The project is currently under construction and is scheduled for completion in early 2010.

The plant is located in the Paraguana peninsula in the Falcon region in northwest Venezuela, an area considered to be one of the driest places in the country. The project at Petroleos de Venezuela SA's (PDVSA) Paraguana Refinery Complex is being designed and built jointly by Spanish water company Acciona Agua and PDVSA. The Paraguana Refinery Complex will utilize approximately 30% of the production capacity, with the remainder supplying a population of 350,000. This will be the largest RO desalination plant in South America and one of the largest plants in the Caribbean region.

EPC contractor Acciona Agua is designing the plant with ERI's energy efficient pressure recovery solution, employing 64 model PX-260 units.

These devices will save the project an estimated 52 mega-watts of energy per year.

This is not the first time Acciona selected PX technology for its desalination projects. Europe's largest facility, the 240,000 m(3)/day (64 MGD) Torrevieja plant in Spain as well as the 100,000 m(3)/day (26 MGD) Fouka project in Algeria, the 60,000 m(3)/day Tordera retrofit plant in Spain and the 16,000 m(3)/day Arucas II plant, also in Spain, are being built by Acciona using PX energy recovery devices. These plants will supply fresh water for municipal, industrial and agricultural applications.

Borja Blanco, ERI Vice President and General Manager of the Mega Projects Division stated, "We consider Acciona Agua to be a premier partner in delivering energy efficient solutions in desalination. They have relied on PX technology for many of their first-of-a-kind projects all over the world." About ERI(R) Energy Recovery, Inc. (ERI) is a leading manufacturer of energy recovery devices which help make desalination affordable by significantly reducing energy consumption. ERI's PX Pressure Exchanger(R) (PX(R)) device is a rotary positive displacement pump that recovers energy from the high pressure reject stream of seawater reverse osmosis (SWRO) systems at up to 98% efficiency with no downtime or scheduled maintenance.

The company has research, development and manufacturing facilities in the San Francisco technology corridor as well as direct sales offices and technical support centers in key desalination hubs such as Madrid, UAE, Shanghai and Florida. ERI service representatives are based in Algeria, Australia, China, India, Korea, Mexico, Taiwan and the Caribbean.

Mar 31, 2009 -- Genzyme Corporation (NASDAQ: GENZ) announced today that it has entered into an agreement to acquire the worldwide rights to Campath(R) (alemtuzumab) from Bayer HealthCare, giving Genzyme primary responsibility for the development and commercialization of this potential break-though treatment for multiple sclerosis (MS). Bayer will continue to fund a portion of alemtuzumab's development in MS and will retain an option to co-promote the product in MS upon approval. In addition, Genzyme will assume sole responsibility for worldwide sales and marketing for Campath in B-cell chronic lymphocytic leukemia (CLL), where it is indicated for use as a single agent in first-line and previously-treated patients with this disease. Bayer will retain the right to develop and commercialize alemtuzumab in solid organ transplant indications.

The agreement further expands Genzyme's hematologic oncology commercial presence beyond Campath through the addition of Fludara(R) (fludarabine) and Leukine(R) (sargramostim), and provides an opportunity to integrate members of Bayer's experienced commercial team for all three drugs into Genzyme's global operations. Genzyme will acquire a new, Seattle-area Leukine manufacturing facility for $75 to $100 million and hire the plant's operating personnel following FDA plant approval, which is expected in 2010.

The transaction is accretive and already reflected in Genzyme's 2009 revenue and non-GAAP earnings per share guidance. The deal is structured as an earn-out arrangement. Bayer will receive payments based on revenues (subject to an aggregate cap) and potential milestone payments if cumulative revenue targets are achieved. There are no upfront payments for the rights of these three drugs. The transaction would provide Genzyme approximately $185 million in oncology revenue in 2009 and up to $700 million in revenue over the next three years.

Genzyme's Oncology segment revenues in 2008 were $117 million. Today's announcement supports the company's goal of 20 percent compound average non-GAAP earnings growth from 2006 to 2011.

Alemtuzumab in MS "Alemtuzumab is a potentially transformative therapy for the treatment of multiple sclerosis, and an important part of our future. This strategic transaction clarifies the responsibilities of each company and gives Genzyme control over the execution of this program," said Henri A. Termeer, chairman and chief executive officer of Genzyme Corporation. "We will continue to collaborate with Bayer in a more streamlined and focused way." Genzyme is now conducting two Phase 3 studies of alemtuzumab in MS. The first trial, for which enrollment is complete, treats early, active relapsing-remitting patients who have received no prior therapy. The second study, which is expected to complete enrollment before the end of this year, is studying relapsing-remitting patients who had active disease while on other MS therapies. "We are very pleased with the accelerated patient enrollment in our Phase 3 alemtuzumab multiple sclerosis clinical trials, an outgrowth of the positive Phase 2 data published last October," said Mark Enyedy, president of Genzyme Oncology and Multiple Sclerosis. Data from the trials are expected to be available in 2011, and approval is anticipated in 2012.

The Phase 2 study published in the New England Journal of Medicine showed that patients with early, active relapsing-remitting MS experienced significant reductions in the risk of sustained accumulation of disability and annualized relapses after two annual cycles of alemtuzumab when compared with the active comparator Rebif(R) (interferon beta-1a), a currently approved therapy.

Oncology Expansion Campath and Fludara are important therapy options for patients with B-cell chronic lymphocytic leukemia. Both drugs are approved in the United States and Europe as well as in other countries around the world. Leukine, which is marketed in the United States, reduces the incidence of severe and life-threatening infections in appropriate patients with acute myelogenous leukemia (AML) following chemotherapy.

Fludara and Leukine complement Genzyme's hematologic oncology product portfolio.

"Through the acquisition of these hematologic oncology assets, we enhance our commercial presence in the oncology market with a comprehensive product portfolio," said Enyedy. "Genzyme is committed to this important disease area and to deepening our relationship with the specialist providers in this field around the world." The long-term growth of Genzyme Oncology will be driven by regulatory approvals for Mozobil(TM) (plerixafor injection) in new markets and new indications for Clolar(R) (clofarabine injection). The addition of members of Bayer's global commercial team will support the introduction of Mozobil and Clolar for adult AML.

Mozobil, launched in the United States earlier this year, mobilizes hematopoietic stem cells in patients with non-Hodgkin's lymphoma and multiple myeloma for subsequent autologous stem-cell transplants.

Because of the clinical benefits Mozobil offers patients, and the potential economic benefits to transplant centers, the U.S. product launch is proceeding well. European Union approval of Mozobil is expected in the second half of 2009, and additional applications in up to 60 countries are planned.

Clolar is in several clinical trials to secure new therapeutic indications. The U.S. Food and Drug Administration will review Genzyme's supplemental New Drug Application for Clolar to treat adult AML at its September Oncologic Drugs Advisory Committee meeting.

European authorities have asked Genzyme to include in its submission for Clolar in adult AML data from a randomized clinical trial, several of which are ongoing. Clofarabine is currently approved in the United States and Europe (where it is marketed under the tradename Evoltra(R)) for the treatment of acute lymphoblastic leukemia in relapsed and refractory pediatric patients, and has become a standard of care in this setting. Additional approvals are expected in Latin America and Canada this year.

Key Terms of the Agreement The agreement creates efficiencies for the alemtuzumab MS development program, and expands the Genzyme Oncology business unit revenues. The new agreement contains the following key terms: Alemtuzumab in MS -- Genzyme will lead the development program. Bayer, which has been co-developing alemtuzumab in MS with Genzyme, will continue to fund development at current levels until the investigational compound is approved for this indication.

-- After approval, Bayer will receive payments contingent on annual revenue until $1.25 billion in payments is realized. The agreement includes a ten-year time cap on payments. Bayer may also receive future milestone payments as a percentage of worldwide sales beginning in 2021 if Genzyme does not exercise a buyout option in 2020 for up to $900 million.

-- Genzyme will assume primary responsibility for the commercialization. Bayer, which currently markets Betaseron(R) (interferon beta-1b) for MS, retains an option to co-promote alemtuzumab in MS.

Oncology Drugs -- For the oncology drugs Fludara, Leukine, and Campath/MabCampath, Bayer will receive payments contingent on annual revenue, capped at $500 million or eight years.

-- In addition, Bayer could receive $150 million in total milestone payments beginning in 2011 if certain annual revenues are met across a three-year time period.

-- Bayer will supply Fludara and Leukine. Genzyme will take over the production of Leukine following FDA approval of a new, Seattle-area Leukine plant.

The transaction is expected to close in the second quarter, pending Federal Trade Commission review and international regulatory clearances. Genzyme and Bayer will work closely to allow for an orderly transition of drug sales and distribution. This process is expected to take place over a period of months following the close of the transaction, during which Bayer will provide transition services.

Prior to this agreement, Genzyme received two-thirds of Campath net profits on U.S. sales and a significant royalty on foreign sales from Bayer. Genzyme acquired Campath in the 2004 acquisition of Ilex Oncology, while Bayer obtained the marketing and distribution rights to Campath in its 2006 acquisition of Schering, which had been the exclusive distributor of Campath for Ilex. As a precondition to FTC clearance of the Ilex acquisition, Genzyme agreed to divest to Schering the right to develop and commercialize alemtuzumab in solid organ transplant. Bayer will retain such right under this agreement.

About Campath(R) (alemtuzumab) Alemtuzumab is a humanized monoclonal antibody that binds to a specific target, CD52, on cell surfaces and directs the body's immune system to destroy those cells. It is the first and only monoclonal antibody approved by the FDA for the treatment of patients with B-cell chronic lymphocytic leukemia (B-CLL).

Safety Data from the alemtuzumab in MS Phase 2 Trial A total of six alemtuzumab-treated patients, and one Rebif-treated patient, in this study developed a serious adverse event, immune thrombocytopenic purpura (ITP). ITP is a disorder characterized by a low platelet count and corresponding increased risk of uncontrolled bleeding. A patient monitoring program was instituted in the trial.

Common non-serious adverse events in the trial included infusion-associated reactions in the alemtuzumab patients and flu-like symptoms in patients using Rebif. Alemtuzumab-treated patients were more likely than Rebif patients to experience infections, particularly of the upper respiratory tract; infections were predominantly mild to moderate in severity and there were no life-threatening or fatal infections. Though alemtuzumab transiently lowers white blood cell counts, the trial did not show an increased risk of opportunistic infections. Serious infections were infrequent in the alemtuzumab-treated patients. Some alemtuzumab-treated patients developed autoimmune thyroid-related adverse events, including Graves' disease, and were managed using conventional therapies. Alemtuzumab is an investigational drug for the treatment of MS and must not be used in MS patients outside of a formal, regulated clinical trial setting in which appropriate patient monitoring measures are in place.

About Leukine(R) (sargramostim) Leukine(R) (sargramostim) is a growth factor that helps fight infection and disease in appropriate patients by enhancing immune cell function.

Leukine was approved in the United States in 1991. Leukine is the only growth factor approved in the U.S. for use following induction chemotherapy in older adults with acute myelogenous leukemia (AML) to shorten the time to neutrophil recovery and reduce the incidence of severe and life-threatening infections and infections resulting in death. Leukine also has been approved in the U.S. for use in four additional indications: myeloid reconstitution following allogeneic and autologous bone marrow transplantation (BMT), peripheral blood stem cell (PBSC) mobilization and subsequent myeloid reconstitution in patients undergoing PBSC transplantation, and bone marrow transplantation failure or engraftment delay.

About Fludara(R) (fludarabine phosphate for injection) Unlike alkylating cytotoxic chemotherapies, Fludara(R), a purine nucleotide analog, inhibits the synthesis of new DNA, thus preventing leukemia cells from multiplying. The intravenous (i.v.) formulation of Fludara was first approved in 1991 and is available in 98 countries worldwide as a second-line therapy for B-CLL patients who have failed previous treatment with alkylating agents. In addition, Fludara i.v.

has been approved as a first-line therapy of B-CLL in 62 countries. In 29 countries, Fludara i.v. is also approved for the second-line treatment of low grade non-Hodgkin's Lymphoma (lg-NHL). The oral formulation has the same effect as the i.v. formulation and was approved in Europe in 2001.

About Mozobil(TM) (plerixafor injection) Mozobil, a novel small molecule CXCR4 chemokine receptor antagonist, has been shown in multiple earlier studies to rapidly and effectively increase the number of stem cells in circulation in the blood in patients with non-Hodgkin's lymphoma and multiple myeloma. Once circulating in the blood, stem cells can be collected for use in an autologous stem cell transplant.

About Clolar(R) (clofarabine injection) Clolar is indicated in the U.S. for the treatment of pediatric patients one to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens. This use is based on the induction of complete responses. Randomized trials demonstrating increased survival or other clinical benefit have not been conducted.

In the European Union, clofarabine is marketed as Evoltra(R) and Clolar is indicated in ALL pediatric patients who have relapsed or are refractory after receiving at least two prior regimes and where there is no other treatment option anticipated to result in durable response.

Clolar received FDA approval in 2004, and EMEA approval in 2006. Clolar has Orphan Drug designation for adult and pediatric ALL, and seven years of market exclusivity in the United States for relapsed/refractory pediatric ALL. The FDA also granted six months of extended market exclusivity to Clolar under the Best Pharmaceuticals for Children Act.

About Genzyme One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 11,000 employees in locations spanning the globe and 2008 revenues of $4.6 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.

With many established products and services helping patients in approximately 100 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences.

The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune disease, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as cardiovascular disease, neurodegenerative diseases, and other areas of unmet medical need.

Mar 31, 2009 -- Perf Go Green Holdings, Inc. ("Perf Go Green") (OTCBB: PGOG) the leader in biodegradable plastic products and everyday green solutions, today announced its partnership with Six Flags, Inc.

(NYSE:SIX), the world's largest regional theme park company, to support its green initiatives. Six Flags will use Perf Go Green biodegradable commercial trash bags throughout the company's twenty locations in the United States, Mexico and Canada.

"We at Perf Go Green believe in reusing, recycling, and reducing our impact on the environment as much as possible. From development to disposal, all Perf Go Green products respect our cradle-to-cradle philosophy," CEO Tony Tracy said. "Formed with one purpose, one goal in mind -- to stop trashing the planet, and embrace solutions that will help achieve this goal, we are happy to provide more products to meet the demand of the eco-conscious consumer and reach the thousands of people that visit Six Flags each year." "We believe that protecting the environment is everyone's responsibility and we've made a commitment to introduce everyday sustainability solutions within our family of parks," said Mark Quenzel, Six Flags EVP, Park Strategy and Management. "These initiatives will help to ensure healthier environments and more vibrant communities for current and future generations." Perf Go Green commercial trash bags complement the company's existing consumer product line, which currently includes the 13-gallon tall kitchen trash bag and 30- and 39-gallon lawn & leaf bags. Perf Go Green's corporate name reflects its "Go Green" mission to develop market and distribute biodegradable plastic products as a practical solution to eliminating plastic waste from the world environment.

Founded in November 2007, Perf Go Green premiered at the March 2008 International Home and Housewares Show in Chicago, where its products received an honor for their design quality and innovation. One year later, in 2009 Perf Go Green launched 0% cadmium, 0% lead, 0% mercury, PerfPower(tm) Alkaline Batteries with free recycling, through, and their all-natural and sustainable Perf Go Clean(tm) line of household and commercial cleaning products.

About Perf Go Green Perf Go Green, Holdings Inc. is a New York-based biodegradable plastics company. The corporate name reflects the "Go Green" mission from inception to create a Green company for the development and global marketing of eco-friendly, non-toxic, food contact compliant, biodegradable plastic products as a practical and viable solution to eliminating plastic waste from the world environment.

Mar 31, 2009 -- Patriot Energy Corporation (PINKSHEETS: PGYC) is pleased to report that Pink Sheets Electronic OTC Markets has accepted all current information filed and consequently officially updated Patriot Energy Corporation's information as of March 30, 2009.

By filing all current and updated company information, lifts the caveat and as a result the public is presented with the opportunity to see a complete overview of the business, management team, board members and financial condition of Patriot Energy Corporation, through the most recent period ending February 28th, 2009.

Patriot Energy Corporation is committed to assure transparency for its shareholders and investors by maintaining all company information current. Investors and other interested parties may view this filing on

About Patriot Energy Corporation Patriot Energy Corp. is a management holding corporation, which owns a wholly owned subsidiary named TelTeck Solutions and owns a 99 year exclusive leased license agreement with Tectane Technologies Corporation for the Dual H2O Engine Oxygenator and New Tri-Brid Engine (Electric/Flex-Fuels/H2O) Technologies. Patriot Energy specializes in the development and marketing of energy efficient technologies with a focus on reducing America's dependence on Foreign Oil.

Total Shares Outstanding (fully diluted): 199,500,000 Mar 31, 2009 -- Stem Cell Therapy International, Inc. (OTCBB: SCII) -- soon to be known as AmStem International after a successful merger with Histostem Ltd, of South Korea ("the Company") -- is proud to announce today that the Company is now ready to replicate, on an international scale, the remarkably successful Stem Cell Leadership Program developed by Dr. Hoon Han in South Korea. The Company and Histostem Ltd. leaders will collaborate to establish a dynamic system -- that can be operated virtually anywhere in the world -- of stem cell collection, storage, research and therapeutic services, based on the proven success of Histostem, Ltd. in Asia.

"We will be creating a mentoring system from AmStem's proprietary technologies (as acquired from Histostem Ltd's state-of-the-art facilities and accomplished clinical successes) to launch a program of leadership and replication that will exponentially increase our revenue-producing and product development operations," announced David Stark, President of AmStem International. "We already have our first amazing new product ready to roll out, which will be announced in the next few days," he added, "And I have personally been negotiating with government officials and leading clinics in other countries; making excellent progress toward our mutual goals." "Our proven combination of cord blood collection and storage, ethically-based clinical trials, and therapeutic applications of promising technologies will be a boon to the economy of any country, and will allow us to make new scientific discoveries in collaboration with international stem cell leaders," he added. "Basically, we will be replicating the incredible success that Histostem has had in South Korea; greatly expanding our revenue-producing and product development operations in a dynamic, modern, international setting." Histostem Ltd. currently operates the largest accredited cord blood and stem cell bank in the world (more than twice as large as its nearest competitor), and is already successfully treating hundreds of patients with patented, Korean FDA-approved stem cell therapies derived from its own sources. It is one of the few stem cell companies in the world that is profiting from its stem cell operations. "To my knowledge, no other company in the world has the type of approval from its home country's regulatory agencies that Histostem Ltd. has from the Korean FDA," affirmed Mr. Stark. "This in effect gives us carte blanche to study the treatment of virtually any appropriate medical condition with stem cells as an approved 'surgical technique,'" he added. "We can use this precedent to seek similar approvals in other countries that want to come to the forefront of the international stem cell stage." "Adult stem cell technology is far less controversial in many countries than embryonic stem cells," explained Dr. Han. "We will immediately explore the fantastic revenue opportunities for offering world-class stem cell treatment from Histostem's patented technologies in receptive international settings, which would also establish a robust and ethical clinical trials program that will benefit the local population for years to come." About Stem Cell Therapy International, Inc.

Stem Cell Therapy International, Inc. ('SCII') is in the field of regenerative medicine. SCII is a company devoted to the treatment of patients with stem cell transplantation therapy as well as providing the supplies of biological solutions containing new lines of stem cell products.

About Histostem Corporation, Ltd: Histostem, Co., Ltd. started in Seoul, Korea in 2000. To date it has treated more than 500 patients with stem cells and currently have 56 full-time employees and 28 part-time employees. Histostem's intellectual property portfolio consists of five patents that have been granted and 6 patents pending. To its knowledge Histostem is one of the very few stem cell companies in the world currently earning several million dollars in income from its products and technology.

About has become one of the premier stops for investors who wish to experience huge profits via investing in up-and-coming publicly traded companies. email report service is free to those investors who sign up on our website. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to OTCBB and Pinksheet companies that have the potential of showing increased activity and Standing Out from the rest of the market. To subscribe to this free service, visit the Standout StocksReport home page at and select the "join now" button.

Join us at for a complimentary subscription to the most exciting online financial newsletter on the market.

Disclaimer: Verify all claims and do your own due diligence. profiles are not a solicitation or recommendation to buy, sell or hold securities. is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b), is owned and operated by Neither nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in statements and opinions and such statements and opinions cannot be considered independent. and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. services are often paid for using free-trading shares. may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.

Visit us for a full Disclaimer at: CONTACT: e-mail: ((M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties.

Further information on M2 PressWIRE can be obtained at on the world wide web. Inquiries to

Copyright ? 2009 M2 Communications Ltd.

[ Back To's Homepage ]

Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments:
Comments about this site:


© 2019 Technology Marketing Corporation. All rights reserved | Privacy Policy